research use only
Cat.No.S7317
| Related Targets | PI3K Akt mTOR GSK-3 ATM/ATR DNA-PK PDPK1 PTEN PP2A PDK |
|---|---|
| Other AMPK Inhibitors | Dorsomorphin Dihydrochloride Dorsomorphin (Compound C) AICAR (Acadesine) A-769662 GSK621 Ex229 (Compound 991) Phenformin HCl BAY-3827 HTH-01-015 O-304 |
| Molecular Weight | 496.99 | Formula | C25H29ClN6O3 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 1214265-58-3 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | CCC(=O)NC1=CC(=CC=C1)OC2=NC(=NC=C2Cl)NC3=C(C=C(C=C3)N4CCN(CC4)C)OC | ||
|
In vitro |
DMSO
: 10 mg/mL
(20.12 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Targets/IC50/Ki |
NUAK1
(Cell-free assay) 20 nM
NUAK2
(Cell-free assay) 100 nM
|
|---|---|
| In vitro |
In HEK-293 cells expressing wild-type NUAK1, WZ4003 (3–10 μM) markedly suppresses NUAK1-mediated MYPT1 phosphorylation. Moreover, this compound (10 μM) inhibits MYPT1 Ser445 phosphorylation as well as cell migration, invasion and proliferation to a similar extent as knock out in MEFs or knock down in U2OS cells of NUAK1. It also exhibits a high, specific affinity to the L858R/T790M mutant EGFR, while a significantly reduced cellular IC50 against T790M containing Ba/F3 cells.
|
| Kinase Assay |
IC50 determination
|
|
Active GST–NUAK1, GST–NUAK1[A195T] and GST–NUAK2 enzymes are purified using glutathione–Sepharose from HEK-293 cell lysates 36–48 h following the transient transfection of pEBG2T mammalian constructs expressing N-terminal GSTtagged NUAK1, NUAK1[A195T] or NUAK2. For peptide kinase assays, 96-well plates are used, and each reaction is performed in triplicate. Each reaction is set up in a total volume of 50 μL containing 100 ng of NUAK1 (wild-type or A195T mutant) or NUAK2 in 50 mM Tris/HCl (pH 7.5), 0.1 mM EGTA, 10 mM magnesium acetate, 200 μM Sakamototide, 0.1 mM [γ -32P]ATP (450–500 c.p.m./pmol) and the indicated concentrations of inhibitors dissolved in DMSO. After incubation for 30 min at 30°C, reactions are terminated by adding 25 mM (final) EDTA to chelate the magnesium. Then, 40 μL of the reaction mix is spotted on to P81 paper and immersed in 50 mM orthophosphoric acid. Samples are washed three times in 50 mM orthophosphoric acid followed by a single acetone rinse and air drying. The incorporation of [γ -32P]ATP into Sakamototide is quantified by Cerenkov counting. The values are expressed as a percentage of the DMSO control. IC50 curves are developed and IC50 values are calculated using GraphPad Prism software.
|
References |
|
| Methods | Biomarkers | Images | PMID |
|---|---|---|---|
| Western blot | Tau-5 / p-tau (Ser356) |
|
27720485 |
| Immunofluorescence | YAP/TAZ |
|
30158528 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.